Item 8.01. Other Events.

On May 6, 2021, the Company issued a press release announcing twelve and twenty-four month data from certain dosing groups in its ongoing X-linked retinitis pigmentosa (XLRP) phase 1/2 clinical trial. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



               Exhibit No.   Description

               99.1            Press release dated May 6, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses